Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

1(17%)

Results Posted

60%(3 trials)

Phase Distribution

Ph phase_4

17%

Ph not_applicable

83%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 4Post-market surveillance

1(16.7%)

N/ANon-phased studies

5(83.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Detailed Status

Completed5

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 41 (16.7%)

N/A5 (83.3%)

Trials by Status

completed583%

active_not_recruiting117%

Recent Activity

1 active trials

Showing 5 of 6

active_not_recruitingnot_applicable

Feasibility of Delivering VergeRx at FQHCs

NCT06161675

completednot_applicable

SmokefreeSGM, A Text-based Smoking Cessation Feasibility Trial for Sexual and Gender Minority Groups

NCT05645354

completednot_applicable

Clinical Trials (6)

Showing 6 of 6 trials

NCT06161675Not Applicable

Feasibility of Delivering VergeRx at FQHCs

Active Not Recruiting

NCT05645354Not Applicable

SmokefreeSGM, A Text-based Smoking Cessation Feasibility Trial for Sexual and Gender Minority Groups

Completed

NCT06111755Not Applicable

Quit Smoking Text Message Study

Completed

NCT05055778Not Applicable

Establishing the Effectiveness of Publicly Available Smoking Cessation Resource

Completed

NCT03538938Phase 4

Improving Quitline Support Study

Completed

NCT03982576Not Applicable

Innovations to Prevent Relapse Among Low-income African American Smokers

Completed

All 6 trials loaded

Drug Details

Intervention Type: BEHAVIORAL
Total Trials: 6